Iron overload emerges as a serious complication in myelodysplastic syndromes (MDS), particularly associated with frequent transfusions during the course of the disease. The discovery and description of hepcidin’s mechanisms of action have contributed to a deeper understanding of iron metabolism. The existing literature reports a potential role of hepcidin in MDS, yet these data are fragmented and presented in an unstructured, somewhat chaotic manner. Hence, to address the existing data, we performed a systematic review of observational studies examining hepcidin levels in MDS. An extensive review of three bibliographic databases (Pubmed, Web of Science, and Scopus) enabled us to identify 12 observational studies. These studies focused primarily on adult patients with low-risk MDS who underwent transfusions and chelation therapy. An in-depth analysis of these manuscripts led to four main conclusions: (1) although high serum hepcidin levels are associated with MDS, most studies generally have not found a significant difference in these levels between patients and healthy individuals; (2) serum hepcidin levels are specific to MDS type; (3) serum hepcidin levels in MDS are strongly associated with transfusions and the genetic status of patients; and (4) high-risk MDS is associated with high serum hepcidin levels. While we have furnished a comprehensive summary of the significance of hepcidin in MDS, there are still gaps that future research should address. This pertains primarily to the capacity of hepcidin in predicting adverse outcomes for MDS patients and evaluating the efficacy of chelation therapy or the need for transfusion.
铁过载是骨髓增生异常综合征（MDS）中一种严重的并发症，尤其与疾病过程中频繁输血密切相关。铁调素作用机制的发现和阐述深化了人们对铁代谢的理解。现有文献报道了铁调素在MDS中的潜在作用，但这些数据较为零散，且呈现方式缺乏系统性，略显混乱。为此，我们对探讨MDS患者铁调素水平的观察性研究进行了系统性综述，以整合现有数据。通过对三个文献数据库（Pubmed、Web of Science和Scopus）的全面检索，我们最终确定了12项观察性研究。这些研究主要关注接受输血和螯合治疗的低危MDS成年患者。对这些文献的深入分析得出以下四个主要结论：（1）尽管高血清铁调素水平与MDS相关，但多数研究未发现患者与健康个体间的铁调素水平存在显著差异；（2）血清铁调素水平具有MDS亚型特异性；（3）MDS患者的血清铁调素水平与输血情况及患者基因状态密切相关；（4）高危MDS与高血清铁调素水平相关。尽管本研究系统总结了铁调素在MDS中的意义，但未来研究仍需填补现有空白，这主要涉及铁调素在预测MDS患者不良预后、评估螯合治疗效果或输血需求方面的能力。
肿瘤(癌症)患者之家